Xenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per Share
Equities analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report earnings of ($0.48) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.49). Xenon Pharmaceuticals reported earnings of ($0.43) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.6%. The firm is scheduled to issue its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.79) to ($1.21). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.88) to ($1.49). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.34). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $6.38 million. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%.
Hedge funds have recently bought and sold shares of the stock. Sabby Management LLC raised its stake in Xenon Pharmaceuticals by 7.1% during the 4th quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after buying an additional 21,800 shares during the period. K2 Principal Fund L.P. raised its stake in Xenon Pharmaceuticals by 33.5% during the 4th quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 55,033 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Xenon Pharmaceuticals by 59.2% during the 4th quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after buying an additional 92,600 shares during the period. 64.62% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:XENE opened at $5.45 on Thursday. The stock has a market capitalization of $74.40, a PE ratio of -3.17 and a beta of 0.74. The company has a debt-to-equity ratio of 0.17, a quick ratio of 10.99 and a current ratio of 10.98. Xenon Pharmaceuticals has a 1 year low of $2.10 and a 1 year high of $5.80.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/04/17/xenon-pharmaceuticals-inc-xene-expected-to-post-earnings-of-0-48-per-share.html.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.